PatientsVille.com Logo

EPISTAXIS and SPIRONOLACTONE

PatientsVille

EPISTAXIS Symptoms and Causes

Your nose is important to your health. It filters the air you breathe, removing dust, germs, and irritants. It warms and moistens the air to keep your lungs and tubes that lead to them from drying out. Your nose also contains the nerve cells that help your sense of smell. When there is a problem with your nose, your whole body can suffer. For example, the stuffy nose of the common cold can make it hard for you to breathe, sleep, or get comfortable.

Many problems besides the common cold can affect the nose. They include

  • Deviated septum - a shifting of the wall that divides the nasal cavity into halves
  • Nasal polyps - soft growths that develop on the lining of your nose or sinuses
  • Nosebleeds
  • Rhinitis - inflammation of the nose and sinuses sometimes caused by allergies. The main symptom is a runny nose.
  • Nasal fractures, also known as a broken nose

Check out the latest treatments for EPISTAXIS

EPISTAXIS treatment research studies

SPIRONOLACTONE clinical trials, surveys and public health registries


Find Drug Side Effect reports



SPIRONOLACTONE Side Effects

Hyperkalaemia (208)
Renal Failure Acute (103)
Dyspnoea (81)
Dehydration (59)
Asthenia (56)
Gynaecomastia (55)
Diarrhoea (52)
Nausea (50)
Blood Potassium Increased (50)
Blood Creatinine Increased (48)
Fatigue (46)
Hypotension (43)
Renal Failure (41)
Dizziness (40)
Pain (37)
Bradycardia (36)
Vomiting (33)
Hyponatraemia (33)
Oedema Peripheral (31)
Atrial Fibrillation (28)
Renal Impairment (28)
Condition Aggravated (27)
Malaise (26)
Chest Pain (25)
Cardiac Failure (25)
Cough (25)
Fall (25)
Anaemia (24)
Pyrexia (23)
Pruritus (23)
Back Pain (22)
Rash (22)
Death (21)
Hypertension (21)
Blood Urea Increased (20)
Anxiety (20)
Blood Pressure Decreased (20)
Cardiac Failure Congestive (20)
Headache (20)
Weight Increased (19)
Pulmonary Embolism (18)
Blood Pressure Increased (18)
Breast Pain (18)
Confusional State (17)
Weight Decreased (17)
Hypokalaemia (17)
Syncope (16)
Pneumonia (16)
Myocardial Infarction (16)
Oedema (15)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

EPISTAXIS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Conditions: Epistaxis;   Hereditary Hemorrhagic Telangiectasia
Intervention: Drug: Sodium tetradecyl sulfate (sotradecol)
Outcome Measures: Frequency of Epistaxis;   Severity of Epistaxis;   Hemoglobin level;   Tolerability of sclerotherapy;   Patient's need for additional treatment;   Overall quality of life
2 Recruiting Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Conditions: Hereditary Hemorrhagic Telangiectasia;   Epistaxis
Interventions: Drug: Bevacizumab;   Drug: placebo
Outcome Measures: mean duration of Epistaxis;   adverse events;   mean monthly Epistaxis duration;   frequency and duration of Epistaxis;   Quality of life;   Number of red blood cells transfusion;   Change in hemoglobinemia and serum ferritin;   Kinetics of monthly Epistaxis duration
3 Recruiting North American Study of Epistaxis in HHT
Conditions: Telangiectasia, Hereditary Hemorrhagic;   Epistaxis
Interventions: Drug: Sterile saline;   Drug: Bevacizumab;   Drug: Estriol;   Drug: Tranexamic Acid
Outcome Measures: Frequency of Epistaxis;   Duration of Epistaxis;   Hoag Epistaxis Severity Score;   Short Form-36 Health Survey;   Supplemental Epistaxis Questionnaire;   Hemoglobin level and ferritin levels;   Units of RBC transfused;   Treatment failure
4 Unknown  Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
Conditions: Hereditary Hemorrhagic Telangiectasia;   Epistaxis
Intervention: Drug: Thalidomide
Outcome Measures: Percentage of patients showing a decrease in the frequency, intensity and duration of Epistaxis and in the blood transfusion requirement.;   Size and number of telangiectasias evaluated by endoscopy of nasal mucosa (recording images of the size and localization of telangiectasias);   Minimum dose of the drug that reduces bleeding;   Time to response;   Time to relapse after the end of treatment;   Number of adverse events;   Correlations between biological parameters, response to treatment and side effects profile
5 Unknown  Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Condition: Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention: Drug: Submucosal Bevacizumab
Outcome Measure: Epistaxis using the Epistaxis Severity Score, hematocrit, hemoglobin and serum feritin levels..
6 Unknown  A Prospective Randomised Controlled Trial of Management of Recurrent Nosebleeds in Children
Condition: Epistaxis
Intervention: Procedure: Nasal Cautery
Outcome Measure:
7 Unknown  Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Condition: Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention: Drug: Bevacizumab
Outcome Measure: Measurement of Epistaxis in patients with HHT as measured by the HHT foundation Epistaxis Severity Score, hematocrit, hemoglobin and serum ferritin levels.
8 Recruiting Long Term Results and Complications After Epistaxis Treatment
Condition: Nosebleed (Epistaxis) - Posterior or Anterior
Intervention:
Outcome Measures: Number of patients without recurrence;   Discomfort caused by treatment
9 Not yet recruiting Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose
Condition: Rendu Oser Weber Syndrome
Intervention: Drug: bevacuzimab
Outcome Measure: decrease of at least 50% of number of Epistaxis in a month compared to the month before inclusion.
10 Recruiting A Novel Anterior Rhinoscopic Scoring Scale to Predict Nasal Insertability Before Transnasal Endoscopy
Conditions: Injury Due to Endoscopic Examination;   Transnasal Endoscopy Induced Epistaxis;   Transnasal Endoscopy Induced Nasal Pain
Interventions: Procedure: anterior meatoscopy;   Procedure: Nasal sniff test
Outcome Measures: The primary outcome measures were tolerability profiles on a validated visual analogue scale;   Secondary outcome measure evaluates the side effects of transnasal endoscopy
11 Recruiting Double Versus Single Pledget Nasal Anesthesia for Transnasal Endoscopy
Conditions: Anesthesia;   Epistaxis
Interventions: Device: Double pledget nasal anesthesia (DPNA);   Device: Single pledget nasal anesthesia (SPNA)
Outcome Measures: The primary outcome measures are tolerability profiles on a validated visual analogue scale;   Secondary outcome measures evaluate the side effects of nasal anesthesia
12 Recruiting Iron Deficiency and Hereditary Haemorrhagic Telangiectasia
Condition: Hereditary Haemorrhagic Telangiectasia
Intervention: Drug: Ferrous sulphate 200mg oral tablet
Outcome Measure: Blood iron indices
13 Unknown  Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire
Condition: Acute Idiopathic Thrombocytopenic Purpura
Intervention:
Outcome Measure:
14 Unknown  Tranexamic Acid in Dacryocystorhinostomy
Condition: Nasolacrimal Tract Obstruction
Interventions: Drug: Tranexamic acid;   Drug: saline solution
Outcome Measures: Duration of DCR surgery in minutes and amount of blood loss in milliliters during surgery.;   Late onset postoperative Epistaxis or periorbital hematoma
15 Recruiting Study of Nasal Airflow Pressure Optimization to Resolve Excessive Snoring
Condition: Habitual, Simple Snoring
Intervention: Device: nasal continuous positive airway pressure less than or equal to 6 cm H2O
Outcome Measures: Efficacy - The Cloud9™ device is expected to reduce the incidence of snoring.;   Safety - Adverse events associated with CPAP (nasal or skin irritation, Epistaxis and sleep disruption) will occur in few subjects.
16 Recruiting The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
Condition: Glanzmann Thrombasthenia
Intervention:
Outcome Measure:
17 Not yet recruiting A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.
Condition: Purpura, Thrombocytopaenic, Idiopathic
Interventions: Drug: Belimumab;   Drug: Normal saline placebo
Outcome Measures: Platelet count;   Anti-platelet autoantibodies;   Platelet count (time);   Platelet count (incidence);   Platelet count (incidence of complete response);   Platelet count (incidence of doubling);   Vital signs;   Clinical chemistry and haematology;   Immunogenicity;   Serum concentrations of belimumab;   Serum and/or platelet bound anti-platelet antibodies;   B cell and T cell sub-populations and B lymphocyte stimulator (BLyS) receptor;   Antigen-specific B cells and T cells;   Serum cytokine/chemokine profile;   Transcriptome profile;   Autoantibody profile
18 Recruiting Thrombocytopathy in Gaucher Disease Patients
Conditions: Gaucher Disease;   Thrombocytopathy
Intervention:
Outcome Measures: Measure thrombocytopathy in a cohort of 70 Gaucher patients using a set of platelet function tests.;   Evaluating the impact of Imiglucerase treatment on platelet function